Connect with us

News

London based CFI.co Announces Mack International as Winner of the 2020 award for: Best Investment Manager Executive Search Firm United States

gbafNews28

CHICAGO, Nov. 22, 2020 /PRNewswire-PRWeb/ — Chicago-based Linda Mac Mack International led by Linda C. Mack is the premier boutique firm specializing in providing C-suite retained executive search and strategic consulting solutions to family offices, family investment firms and family enterprises. Mack International's family clients range from first-generation business-owning wealth creators/entrepreneurs to multi-generational families of six or more generations. Clients also include multi-client family offices, investment and wealth management firms that serve family offices, and UHNW private investors on a global basis. This deep specialization in the family office/investment niche and unique approach was recently recognized by CFI.co, a print journal and online resource reporting on worldwide trends and market in business, economics, and finance.

The CFI.co judge's panel cited Mack International's “comprehensive, consultative approach (has) consistently delivered results for its national and international clients” over the years and “profound understanding of its selected clients and candidates, taking their needs and aspirations into account to create ideal, enduring partnerships.”

Highlights of the judging panel's findings include:

  • Mack International tailors executive search solutions for family offices and family investment firms as well as multi-client family offices, and wealth and investment firms that serve UHNW and family office clients.
  • A dedicated team of senior consultants with over 60 years of combined experience in Family Office and Investment Management personally conducts each assignment. The firm's founder leads every search. No client work is delegated to junior staff.
  • Mack International has weathered the challenges brought about by the coronavirus pandemic with characteristic aplomb. Video Conferencing has given the firm the ability to maintain face-to-face contact with clients and candidates, albeit at a distance, in a convenient format.

The panel described Linda Mack as an industry thought leader acknowledged as one of the world's top wealth management experts. “Mack International is renowned for their proprietary methodology, culling candidate lists until only those with a winning combination of suitable qualifications and cultural fit remain.” Linda commented, “It takes an investor to find an investor. The depth of our team's experience in the investment industry combined with the relationships we have built over many years provide us unparalleled access to the family office and private investor communities. Our distinct competency is not only in finding candidates others cannot get to but in being able to assess the caliber of their investment style, philosophy, and performance. We identify the CIO who not only has the requisite experience and track record of performance but who is also the right culture fit—a leader aligned with our clients' vision, values, and philosophies to successfully achieve their goals.”

By using resourceful and creative approaches tailored to each engagement, Mack International has helped ensure success for their clients this year despite the limitations imposed on in-person meetings. According to Linda, the firm was quickly able to pivot during the COVID crisis. “We were able to help many families that needed to make a crucial hire find their “match,” make an offer and successfully hired their candidate.”

“My heartfelt appreciation to Cfi.co. What an honor it is to accept this repeat award for our expertise in investment management executive search,” said Linda. “It is a privilege to be acknowledged for our continued commitment to excellence.”

About Mack International LLC
Mack International is the premier, boutique retained executive search and strategic management/human capital consulting firm serving national and international clients. The firm serves family office, investment, and enterprise clients as well as wealth and investment management firms who serve family offices, UHNW private investors, foundations, and other philanthropic clients. Founded in 2002, the firm has achieved an exceptional track record of success as evidenced by its unmatched industry expertise, in-depth market knowledge, and unparalleled track record of success. Founder and President, Linda C. Mack has established proprietary methodologies such as the Mack 360© and is credited for having coined the term “expert generalist” in the industry.

About CFI.co
CFI.co is a print journal and online resource reporting on business, economics, and finance. The journal recognizes that the traditional distinction between emerging and developed markets is now far less meaningful as world economies converge. Headquartered in London, the world's most multicultural city, CFI.co covers, and analyses the drivers behind that change.

Combining the views of leading multilateral and national organizations with thought leadership from some of the world's top minds – CFI.co's dedicated editorial team ensures that readers better understand the forces influencing and reshaping the global economy.

Firmly established in a small but crucial niche of the recruitment market, Mack International attracts clients from all over the world. Mack International is not an embellished headhunter; it is, rather, a boutique purveyor of closely-matched talent that operates stealthily, seeking out the best and providing a seamless cultural fit.

.

Media Contact

Isabel Bolt, Mack International, 8173015461, [email protected]

 

SOURCE Mack International

News

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

gbafNews28

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (Takeda) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business.

In June, the firms announced an agreement under which Celltrion would acquire 18 “Primary Care” product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, “Celltrion Asia Pacific Pte, Ltd.”1 (“Celltrion APAC”).

Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.

The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi in particular are expected to contribute to a stable revenue growth as the product patents will be protected until 2026 and 2027, respectively.

Celltrion Pharm, a Celltrion subsidiary, will be a primary domestic distributor, while Celltrion Healthcare will distribute internationally, leveraging its sales networks in Southeast Asia and Australia. Celltrion has entered into a manufacturing and supply agreement with Takeda who will continue to manufacture the divested products for stable product supply and some of the products for local and international market will be manufactured at Celltrion Pharms cGMP production facilities in future.

The acquisition provides Celltrion group an opportunity to strengthen its small molecule pharmaceutical product portfolio and progress towards a market leading position as a global biopharmaceutical company.

Celltrion group also expects this transaction to help position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.

Based on its own R&D capacities and to-be acquired product patents, Celltrion plans to speed up the development of new medicines such as extended-release drugs and compound drugs, as well as biosimilar insulins to complete the portfolio of diabetic and hypertensive pipelines.

Celltrion CEO Kee Woosung said “With the successful acquisition of select primary care and OTC product assets from Takeda in Asia Pacific Celltrion has set an important opportunity to develop additional new drugs and expand its market share in the region,” and “Celltrion will also do its best to secure a leading position in the Asia Pacific market and provide high quality medical products in the region.”

About Celltrion, Inc

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and ECs approval for Inflectra and Remsima, respectively, which is the worlds first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and ECs approval for Truxima and Herzuma. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.


1 Celltrion Asia Pacific PtE. Ltd.

Celltrion, Inc.

Eunyoung Lee, +82 32 850 4384

[email protected]

Or

Tae-Gyun Kim, +82 32 850 5136

[email protected]

Continue Reading

News

Arcturus Therapeutics to Present at Upcoming Investor Conference

gbafNews28

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at Piper Sandlers 32nd Annual Virtual Healthcare Conference:

The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to be Answered into 2021

Panel Presentation Date: Tuesday, Dec 1, 2020 Time: 10:00 a.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR„¢ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

(858) 900-2682

[email protected]

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

[email protected]

Continue Reading

News

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

gbafNews28

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a kidnapping on one of its product tanker vessels, the Agisilaos, as it was approaching the port of Lome, Togo on November 29, 2020.  The vessel is managed and crewed by Capital Ship Management Corp. (˜Capital) who informed Diamond S about the kidnapping of four crew members. The Company confirms that there were 22 seafarers aboard when the attack occurred.  There have been no reports of injuries at this time. All appropriate authorities have been notified and Diamond S is fully supporting Capital as they respond to this situation. Diamond S will not comment further on these operational issues to avoid potentially jeopardizing the safety of the crew members being held or prolonging their stay in captivity.

About Diamond S Shipping Inc.

Diamond S Shipping Inc. (NYSE Ticker: DSSI) owns and operates 66 vessels on the water, including 15 Suezmax vessels, one Aframax and 50 medium-range (MR) product tankers. Diamond S Shipping is one of the largest energy shipping companies providing seaborne transportation of crude oil and refined petroleum products in the international shipping markets.  The Company is headquartered in Greenwich, CT.  More information about the Company can be found at www.diamondsshipping.com.

Investor Relations Inquiries:

Robert Brinberg

Tel: +1-212-517-0810

E-mail: [email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News17 mins ago

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (Takeda) in Asia Pacific,...

gbafNews28 gbafNews28
News17 mins ago

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced the completion of its previously-announced sale of a portfolio of select products...

gbafNews28 gbafNews28
News17 mins ago

Diamond S Shipping Inc. Comments on an Incident Involving One of Its Vessels

Diamond S Shipping Inc. (NYSE: DSSI) (Diamond S or the Company) announced the receipt of an incident report involving a...

gbafNews28 gbafNews28
News17 mins ago

Arcturus Therapeutics to Present at Upcoming Investor Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development...

gbafNews28 gbafNews28
News19 mins ago

KBRA Assigns Ratings to Sunnova Sol II Issuer, LLC, Series 2020-2

Kroll Bond Rating Agency (KBRA) assigns ratings to two note classes issued by Sunnova Sol II Issuer, LLC, Series 2020-2....

gbafNews28 gbafNews28
News27 mins ago

Laura J. Schumacher Joins CrowdStrike’s Board of Directors

CrowdStrike Holdings, Inc. (Nasdaq: CRWD), a leader in cloud-delivered endpoint and workload protection, today announced the appointment of Laura J....

gbafNews28 gbafNews28
News33 mins ago

Cornerstone Community Bancorp Announces Stock Repurchase Plan

Cornerstone Community Bancorp, (OTC Pink: CRSB), the parent company of Cornerstone Community Bank, announced today that its Board of Directors...

gbafNews28 gbafNews28
News47 mins ago

VIQ Solutions Reports Third Quarter Results

VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX Venture Exchange: VQS and OTC Markets: VQSLF) a global provider of secure,...

gbafNews28 gbafNews28
News47 mins ago

Spectra7 Announces Third Quarter Financial Results

(TSX-V:SEV) Spectra7 Microsystems Inc. (Spectra7 or the Company), a leading provider of high-performance analog semiconductor products for broadband connectivity markets,...

gbafNews28 gbafNews28
News47 mins ago

Oshkosh Corporation to Present at the Credit Suisse 8th Annual Virtual Industrials Conference

Oshkosh Corporation (NYSE:OSK), a leading innovator of mission-critical vehicles and essential equipment, announced today that it will present at the...